Effects of Intranasal Oxytocin and Vasopressin on Social Behavior

NCT01296269 | Unknown

• 1 other identifier: OXTandAVP-HMO-CTIL
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and altruism in a healthy population of student controls.

Conditions

Healthy

Keywords

social cognition; oxytocin; vasopressin; decision making; social decision making

Outcome Measures

Primary Outcomes (1)

• allocations of monetary units

  Participants will make decisions regarding the allocation of monetary units between themselves and other participants. We will measure the quantity of monetary units kept for themselves vs. given to other participants

  approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo

Secondary Outcomes (1)

• mood as measured via the visual analog scale

  approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo

Study Arms (3)

Vasopressin

EXPERIMENTAL

vasopressin condition

Drug: Arginine Vasopressin

oxytocin

EXPERIMENTAL

oxytocin condition (syntocinon)

Drug: Oxytocin

placebo

PLACEBO COMPARATOR

Drug: placebo

Interventions

Oxytocin DRUG

one-time intranasal administration, 24 International Units, 5 puffs for each nostril

Also known as: syntocinon

oxytocin

Arginine Vasopressin DRUG

one-time intranasal administration, 20 International Units, 5 puffs in each nostril

Vasopressin

placebo DRUG

contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril

placebo

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• healthy controls

You may not qualify if:

• Past or present psychiatric, neurological, endocrinological or severe chronic medical illness.
• Use of medications or drugs that would interfere with study results. This includes steroids, medications for psychiatric symptoms like anxiety or depression, stimulants, and medications for high blood pressure. Participants will be asked to tell the investigators of any medications or drugs that they are taking. The investigators will consider the drug interactions with oxytocin and vasopressin prior to study, and participants will not be able to participate in the study if the drug interactions could be dangerous.
• history of drug or alcohol addiction
• Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women who are pregnant or nursing are excluded from this protocol. All females will have a pregnancy test performed no more than 24 hours before each drug administration and will not be able to participate if the pregnancy test is positive.

Sponsors & Collaborators

• Hadassah Medical Organization: lead
• Hebrew University of Jerusalem: collaborator

Study Sites (1)

Hadassah University Medical Organization

Jerusalem, Jerusalem, Israel

RECRUITING

MeSH Terms

Conditions

Diabetes Insipidus

Interventions

Oxytocin; Arginine Vasopressin

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormones, Posterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Vasopressins; Neuropeptides; Oligopeptides; Nerve Tissue Proteins; Proteins

Study Officials

• David Mankuta, MD

  Hadassah University Medical Organization

  PRINCIPAL INVESTIGATOR

Central Study Contacts

David Mankuta, MD

CONTACT

972-2-6776484; mankutad@gmail.com

Salomon Israel, MA

CONTACT

972-524789754; salomon.israel@mail.huji.ac.il

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, CARE PROVIDER
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: February 3, 2011
• First Posted: February 15, 2011
• Study Start: April 1, 2011
• Primary Completion: May 1, 2012
• Last Updated: April 8, 2011

Record last verified: 2011-04

Locations

IL (1)